以下部分引用 AI 总结，现阶段 AI 仍然有幻觉。请以内容的原文为准。

数据新鲜度群聊 07-14 ✓卖方 07-14 ✓Wrap 断档15天 ✕News 07-15 ✓X 断档12天 ✕页面生成 07-15

CRL

8 atoms · 跨 2 天 · 首见 2026-05-16 · 最近 2026-06-17

三色: 🟦 fact 3 · 🟥 take 5 · stance ▲7/▼1/◆0

来源: X 8

时态: fresh:5 · aging:3

标签: 好观点:3 · 好数字:3 · 好信源:2

2026-06-17 · 生物制药资金回升转化为订单
strong uptick in biopharma funding beginning to transition into RFPs and bookings
tags: 好观点 · → daily
value: direction=uptick · date=current
2026-06-17 · 竞争优势
we think CRL is well positioned to benefit given its leading preclinical capabilities
tags: 好观点 · → daily
value: description=leading preclinical capabilities

2026-06-17 · 2027年盈利预期上调
we've moved our 2027 EPS estimates up low-single digits
tags: 好数字 · → daily
value: qty=low-single digits · date=2027

2026-06-17 [老化中] · 评级上调
Morgan Stanley Upgrades $CRL to Overweight from Equalweight
tags: 好观点 · → daily
value: direction=upgrade · to=Overweight · from=Equalweight
2026-06-17 [老化中] · 目标价上调
Raises PT to $220 from $185
tags: 好数字 · → daily
value: qty=$220 · from=$185 · date=NA
2026-06-17 [老化中] · 2026年EV/EBITDA估值倍数
implying a 14x 2026E EV/EBITDA multiple, from 12x prior
tags: 好数字 · → daily
value: qty=14x · from=12x · date=2026E

2026-05-16 · CEO 陈述：成熟生物技术公司融资环境
More mature biotechs have better access to capital, as they approach IND or enter the clinic
tags: 好信源 · → daily
value: direction=better access
2026-05-16 · CEO 陈述：早期初创生物技术公司需求状况
demand from start-up biotechs remains tepid because the earlier-stage and seed funding environment remains constrained despite a recent uptick in IPO activity
tags: 好信源 · → daily
value: direction=tepid